Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device
S2CARA
1 other identifier
interventional
664
1 country
24
Brief Summary
A surgery made by an external incision requires to stitch the subcutaneous plans, usually performed using absorbable synthetic sutures hold on wire needle. This national, prospective, multicentric, and randomized study is devoted to estimate a technique of suture of the subcutaneous plans based on an implantable medical device delivering automatically absorbable staples. This particularly innovative technique lets to expect a tolerance and an efficiency at least equivalent to the reference technique (main objective). Moreover, this technique allows to anticipate a reduction of the duration of surgical procedure and anesthetic time while limiting the risks of blood wounds of the medical staff.The medical economic part of this study will check, from the point of view of the health care hospital, wether the technique is likely to reduce the costs and time consuming theater room procedures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2012
Typical duration for phase_3
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 21, 2012
CompletedStudy Start
First participant enrolled
March 1, 2012
CompletedFirst Posted
Study publicly available on registry
March 7, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedMarch 8, 2016
March 1, 2016
2.2 years
February 21, 2012
March 7, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall PSAS score measured 3 months after the surgery
Overall PSAS score measured 3 months after the surgery(PSAS : "Patient Scar Assessment Scale")
3 months after the surgery
Secondary Outcomes (7)
Incremental cost-effectiveness ratio (ICER) or average cost of suture according to the procedure (wire or staple)
Day 0 (Procedure)
Presence of scarring complications at day 8 (infection, dehiscence)
Day 8
Measurement of suture, surgical and anesthetic times
Day 0 (procedure)
Overall score of the PSAS scale
Months 3, 12 and 18
Overall score of the OSAS scale
Months 3, 12 and 18
- +2 more secondary outcomes
Study Arms (2)
Resorbable staples
EXPERIMENTALSuture using Insorb Resorbable staples
Resorbable wires
ACTIVE COMPARATORSuture using Monocryl resorbable wire
Interventions
Subcutanous suture using resorbable staples
Subcutanous suture using resorbable wire
Eligibility Criteria
You may qualify if:
- Male or female aged 18 yrs to 75 yrs
- Patient supported for a scheduled surgery :
- For abdominoplasty, cervicotomy or suprapubic surgery With a open incision necessary for operative exposition of 10 cm or more with a straight or curved surgery incision
- Person covered by Health Insurance
- ECOG Performance Status 0 or 1
- Patient's informed and written consent
You may not qualify if:
- Incision imposing a very angular or sinuous scar for which the use of the medical device is deemed unsuited (sinuous or bayonet incisions)
- Known history of intolerance to any component of the medical device
- Immunocompromised patients or undergoing a long term treatment by corticosteroids or immunosuppressants
- Known or anticipated presence of a skin infection (due to the infected skin condition, or because of underlying surgery conducted in infected territory or likely to be)
- Dermatological disease or skin treatment in progress
- History of radiation therapy on the surgical site or antimitotic treatment in progress
- Pregnancy at the time of suture
- Patients simultaneously included in another treatment protocol
- Patients under legal guardianship
- Non French speaking patients, refusing or unfit for the monitoring proposed in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (24)
CHU de Nantes
Nantes, Pays de la Loire Region, 44000, France
Amiens University Hospital
Amiens, France
Angers University Hospital
Angers, France
Besançon University Hospital
Besançon, France
Bordeaux University Hospital "Centre FX. Michelet"
Bordeaux, France
Brest University Hospital "Hôpital du Morvan"
Brest, France
Caen University Hospital "Hôpital de la Côte de Nacre"
Caen, France
Lille University Hospital "Hôpital Roger Salengro"
Lille, France
"Assistance Publique des Hôpitaux de Marseille - La Conception"
Marseille, France
Montpellier University Hospital "Hôpital Gui de Chauliac"
Montpellier, France
Mulhouse Hospital "Emile Muller"
Mulhouse, France
CHU Nantes
Nantes, France
"Institut de Cancérologie de Nice"
Nice, France
"Assistance Publique des Hôpitaux de Paris - Hôpital Bichat"
Paris, France
CHU Poitiers
Poitiers, France
Poitiers University Hospital
Poitiers, France
Rennes University Hospital "CHU Pontchaillou"
Rennes, France
Rennes University Hospital
Rennes, France
Rouen University Hospital
Rouen, France
Strasbourg University Hospital "Hôpital Hautepierre"
Strasbourg, France
"Institut Claudius Regaud"
Toulouse, France
"Pôle Santé Léonard de Vinci"
Tours, France
Pôle Santé Léonard de Vinci
Tours, France
Tours University Hospital
Tours, France
Study Officials
- PRINCIPAL INVESTIGATOR
Olivier Malard, Professor
Nantes University Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 21, 2012
First Posted
March 7, 2012
Study Start
March 1, 2012
Primary Completion
May 1, 2014
Study Completion
November 1, 2015
Last Updated
March 8, 2016
Record last verified: 2016-03